Clinical Trials Logo
  1. Home
  2. Liposarcoma
  3. NCT01506596

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Liposarcoma Clinical Trial

Official title:
A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness and safety of single agent pazopanib in subjects with unresectable or metastatic liposarcoma.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01506596
Study type Interventional
Source Vector Oncology
Contact
Status Active, not recruiting
Phase Phase 2
Start date March 2012
Completion date June 2016
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT04557449 - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Phase 1/Phase 2
Completed NCT01209598 - PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Phase 2
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2
Not yet recruiting NCT06039046 - Investigating Engagement Patterns and Participation Trends Among Liposarcoma Patients
Recruiting NCT02983539 - Detection of Circulating Tumor Cells in Patients With Sarcomas
Completed NCT02249949 - Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery Phase 2
Completed NCT00093080 - Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) Phase 2
Completed NCT03303885 - The FGF/FGFR Signalling Pathway:
Terminated NCT03959033 - Patient Reported Outcome Measures (PROMs) With Trabectedin
Not yet recruiting NCT06414434 - BTX-A51 in Patients With Liposarcoma Phase 1
Withdrawn NCT03880123 - Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Phase 1
Active, not recruiting NCT02978859 - Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas Phase 2
Recruiting NCT02275286 - Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Phase 1/Phase 2
Completed NCT01426633 - Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas Phase 1
Completed NCT00400569 - Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Phase 2
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT04785196 - APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT02571829 - A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma Phase 2
Completed NCT00060944 - A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer Phase 2